Liquidia Technologies Issues Response To United Therapeutics Suit Alleging Infringement Of Tyvaso Patent: Notes Statutory 30-Month Stay On Regulatory Approval Is Not Associated With Allegations Of '793 Patent, Should Have No Effect On FDA Review